Molecular targeting of malignant gliomas with novel multiply-mutated interleukin 13-based cytotoxins.

[1]  W. Debinski,et al.  Mutants of Interleukin 13 with Altered Reactivity toward Interleukin 13 Receptors* , 1999, The Journal of Biological Chemistry.

[2]  W. Debinski,et al.  Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human high-grade gliomas. , 1999, Clinical Cancer Research.

[3]  S. Powers,et al.  Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme. , 1999, International journal of oncology.

[4]  J. Connor,et al.  Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  J. Rizo,et al.  Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R. Puri,et al.  Novel way to increase targeting specificity to a human glioblastoma‐associated receptor for interleukin 13 , 1998, International journal of cancer.

[7]  R. Puri,et al.  Novel anti–brain tumor cytotoxins specific for cancer cells , 1998, Nature Biotechnology.

[8]  E. Oldfield,et al.  Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors , 1997, Nature Medicine.

[9]  R. McLendon,et al.  Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. , 1997, Cancer research.

[10]  P. Ferrara,et al.  Cloning of the human IL‐13Rα1 chain and reconstitution with the IL‐4Rα of a functional IL‐4/IL‐13 receptor complex , 1997 .

[11]  R. Puri,et al.  The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. , 1997, Journal of immunology.

[12]  R. Puri,et al.  cDNA Cloning and Characterization of the Human Interleukin 13 Receptor α Chain* , 1996, The Journal of Biological Chemistry.

[13]  R. Puri,et al.  Receptor for Interleukin (IL) 13 Does Not Interact with IL4 but Receptor for IL4 Interacts with IL13 on Human Glioma Cells* , 1996, The Journal of Biological Chemistry.

[14]  J. Lélias,et al.  Cloning and Characterization of a Specific Interleukin (IL)-13 Binding Protein Structurally Related to the IL-5 Receptor α Chain* , 1996, The Journal of Biological Chemistry.

[15]  B. Ryffel,et al.  Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common gamma chain. , 1996, Blood.

[16]  J. G. Zhang,et al.  Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  I. Pastan,et al.  Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  B. Scheithauer,et al.  Histopathology, classification, and grading of gliomas , 1995, Glia.

[19]  R. McLendon,et al.  Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. , 1995, Cancer research.

[20]  I. Pastan,et al.  A Novel Chimeric Protein Composed of Interleukin 13 and Pseudomonas Exotoxin Is Highly Cytotoxic to Human Carcinoma Cells Expressing Receptors for Interleukin 13 and Interleukin 4 (*) , 1995, The Journal of Biological Chemistry.

[21]  W. Sebald,et al.  Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency. , 1994, European journal of biochemistry.

[22]  S. Bernasconi,et al.  Regulation of endothelial and mesothelial cell function by interleukin-13: selective induction of vascular cell adhesion molecule-1 and amplification of interleukin-6 production. , 1994, Blood.

[23]  P. Bamborough,et al.  Predictive modelling of the 3-D structure of interleukin-13. , 1994, Protein engineering.

[24]  A Wlodawer,et al.  Structural comparisons among the short-chain helical cytokines. , 1994, Structure.

[25]  G. Zurawski,et al.  Receptors for interleukin‐13 and interleukin‐4 are complex and share a novel component that functions in signal transduction. , 1993, The EMBO journal.

[26]  R. de Waal Malefyt,et al.  Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Casellas,et al.  lnterleukin-13 is a new human lymphokine regulating inflammatory and immune responses , 1993, Nature.

[28]  D. Strickland,et al.  The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. , 1992, The Journal of biological chemistry.

[29]  I. Pastan,et al.  Mutagenesis of Pseudomonas exotoxin in identification of sequences responsible for the animal toxicity. , 1990, The Journal of biological chemistry.

[30]  C. March,et al.  Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily , 1990, The Journal of experimental medicine.

[31]  I. Pastan,et al.  Domain II mutants of Pseudomonas exotoxin deficient in translocation. , 1989, The Journal of biological chemistry.

[32]  I. Pastan,et al.  Mutational analysis of domain I of Pseudomonas exotoxin. Mutations in domain I of Pseudomonas exotoxin which reduce cell binding and animal toxicity. , 1988, The Journal of biological chemistry.

[33]  D. Mckay,et al.  Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Kabat,et al.  NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin,. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Gibo,et al.  Molecular Expression Analysis of Restrictive Receptor for Interleukin 13 , a Brain Tumor-associated Cancer / Testis Antigen , 2000 .

[36]  A. Mintz,et al.  Cancer genetics/epigenetics and the X chromosome: possible new links for malignant glioma pathogenesis and immune-based therapies. , 2000, Critical reviews in oncogenesis.

[37]  W. Debinski,et al.  An immune regulatory cytokine receptor and glioblastoma multiforme: an unexpected link. , 1998, Critical reviews in oncogenesis.

[38]  S. Brem,et al.  Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. , 1998, Journal of neurosurgery.

[39]  I. Pastan,et al.  An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxin. , 1994, Bioconjugate chemistry.

[40]  J. D. de Vries,et al.  Interleukin 13 elicits a subset of the activities of its close relative interleukin 4 , 1994, Stem cells.

[41]  I. Pastan,et al.  Recombinant toxins as novel therapeutic agents. , 1992, Annual review of biochemistry.

[42]  J. Nickoloff,et al.  Site-directed mutagenesis of virtually any plasmid by eliminating a unique site. , 1992, Analytical biochemistry.

[43]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .